Comparing GCB and non-GCB patients from MSK cohort with available matches treated with R-CHOP induction > (R)-ICE consolidation (n = 108) vs matched MER cohort using NNM approach with a 0.2 caliper cutoff treated with R-CHOP (n = 108). (A) EFS; (B) EFS by COO; (C) OS; (D) OS by COO; ∗1 patient at MER had missing EFS data. COO, cell of origin; EFS, event-free survival; GCB, germinal center B-cell like; MER, Molecular Epidemiology Resource; MSK, Memorial Sloan Kettering; NNM, nearest neighbor matching; OS, overall survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; (R)-ICE, rituximab plus ifosfamide, carboplatin and etoposide.